Cure Ventures
Cure Ventures is a venture capital firm focused on life sciences and medical technologies. Founded in 2021 and based in Boston, Massachusetts, the firm concentrates on seed-stage investments in biotechnology, pharmaceuticals, medical devices, and medtech companies with strong growth potential. Its goal is to accelerate the development and market entry of novel cures that address unmet medical needs for patients worldwide by providing capital and strategic support to early-stage ventures, enabling innovative therapies, diagnostics, and related solutions that aim to improve global health outcomes.
3 past transactions
Tasca
Series A in 2024
Tasca is a biotechnology company that offers small molecule drugs for hard-to-treat oncology indications.
Clasp Therapeutics
Series A in 2024
Clasp Therapeutics develops precision oncology platforms to identify neoantigens from driver mutations in hard-to-treat cancers. Its technology enables the creation of targeted therapies that selectively bind to HLA-presented peptides, allowing for precise destruction of cancer cells across various tumor types.
Kenai Therapeutics
Series A in 2024
Kenai Therapeutics specializes in developing innovative therapies for neurodegenerative movement disorders. The company focuses on providing off-the-shelf neuron replacement medicines as effective disease-modifying treatments, enabling doctors to employ new techniques for treating neurological conditions such as Parkinson's.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.